85592-75-2

Usage

InChI:InChI=1/C15H16N2O/c1-11(12-5-3-2-4-6-12)17-15(18)13-7-9-14(16)10-8-13/h2-11H,16H2,1H3,(H,17,18)

Upstream product

• 85592-74-1 p-nitro-N-(1-phenylethyl)benzamide 
• 122-04-3 4-nitro-benzoyl chloride 
• 618-36-0 rac-methylbenzylamine 

Downstream Products

• 108191-15-7 [4-(1-Phenyl-ethylcarbamoyl)-phenyl]-carbamic acid ethyl ester 
• 130566-80-2 para-sirtinol 
• 108267-41-0 4-(Acetylamino)-N-(1-phenylethyl)benzamide 
• 108191-21-5 4-[(1-Phenyl-ethylamino)-methyl]-phenylamine 
• 108191-16-8 N-[4-(1-Phenyl-ethylcarbamoyl)-phenyl]-oxalamic acid ethyl ester 
• 108191-12-4 N-(4-(dimethylamino)phenyl)-2-phenylpropanamide 

Relevant academic research and scientific papers

Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1

Arginine methylation is an epigenetic modification that receives increasing interest as it plays an important role in several diseases. This is especially true for hormone-dependent cancer, seeing that histone methylation by arginine methyltransferase I (PRMT1) is involved in the activation of sexual hormone receptors. Therefore, PRMT inhibitors are potential drugs and interesting tools for cell biology. A dapsone derivative called allantodapsone previously identified by our group served as a lead structure for inhibitor synthesis. Acylated derivatives of p-aminobenzenesulfonamides and the antilepra drug dapsone were identified as new inhibitors of PRMT1 by in vitro testing. The bis-chloroacetyl amide of dapsone selectively inhibited human PRMT1 in the low micromolar region and was selective for PRMT1 as compared to the arginine methyltransferase CARM1 and the lysine methyltransferase Set7/9. It showed anticancer activity on MCF7a and LNCaP cells and blocked androgen dependent transcription specifically in a reporter gene system. Likewise, a transcriptional block was also demonstrated in LNCaP cells using quantitative RT-PCR on the mRNA of androgen dependent genes.

Anticonvulsant activity of some 4-aminobenzamides

A series of 4-aminobenzamides of some simple primary and secondary amines were prepared and evaluated for anticonvulsant effects. The compounds were tested in mice against seizures induced by electroshock and pentylenetetrazole (metrazole) and in the rotorod assay for neurologic deficit. For those N-alkyl amides tested, 4-amino-N-amylbenzamide was the most potent against maximal electroshock seizures (MES): ED50=42.98 mg/kg; however, the N-cyclohexylbenzamide showed the greatest protective index (PI=TD50/ED50), 2.8. The introduction of a second aromatic ring produced more potent compounds, with d,l-4-amino-N-(α-methylbenzyl)-benzamide showing the highest level of activity. This compound has an anti-MES ED50 of 18.02 mg/kg in mice when administered intraperitoneally (ip) and a TD50 of 170.78 mg/kg (PI=9.5) in the same species. These data compare quite favorably with those for phenobarbital and phenytoin in the same assays.

Anti-convulsant

New amino-benzamides and their use for the treatment of epilepsy.